Washington D.C. Sets Model for the Country’s Sustainable Cities

Though major cities sit on just 2% of the world’s available land, together they produce in excess of 77% of the globe’s CO2 emissions. Cities might be major polluters, but they’re also major centers for innovation. That’s made urban cityscapes the focus for sustainability and green efforts by environmental groups.

Washington D.C.’s Green Building Act of 2006 and the D.C. Green Construction Code together have made the nation’s capital a leader in per capita square footage of Leadership in Energy and Environmental Design (LEED) certified space. D.C. has also ranked first for the EPA’s Energy Star cities list for three years in a row. The numerous awards culminated in the U.S. Green Building Council naming Washington D.C. the globe’s very first LEED Platinum City last year.

Using D.C.’s success as a model, cities around the country are looking to boost their sustainability. Observers attribute D.C.’s success to both good construction practices and green-conscious urban planning. Cultivating a tree canopy, paving more bike lanes, and pushing for more walkable cities are all steps in the process toward making cities around the world friendlier for the earth and, as a consequence, friendlier for humans.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More